Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for Oral Premalignant Lesions
NCT00951379Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Feb 2010
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of pioglitazone in oral leukoplakia, sponsored by National Cancer Institute. Started Feb 2010; status: terminated.
02
Drugs
pioglitazone
03
Conditions
oral leukoplakia
Beyond the preview
Go deeper on NCT00951379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00951379.